BRISPR®
Bacteria platform to deliver RNA and protein
We have a strong preclinical pipeline fully owned and IP-protected. Our engineered bacteria deliver diverse cargos larger than other vehicles can handle, and are equipped with safety switches and other smart controls.
Disease areas
-
Cancer
- Lead asset RONC1 against pancreatic cancer
-
Genetic diseases
- Collaboration with large-cap pharma in progress

Targeted
Target the right cells in the right tissues
Selective self-amplification
Enhance efficacy where needed
We welcome additional industry partnerships. Please contact us for further details.